Is Royalty Pharma plc (RPRX) Overvalued?
We dive into why Royalty Pharma plc (RPRX) could be considered overvalued on 2026-07-20, based on AAII’s Value Score and Grade.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
Commentary & Analysis
What You Need to Know About Royalty Pharma plc's Q2 Earnings
Royalty Pharma plc's fiscal Q2 earnings report was released on Wednesday, May 06. Let's dive in to see if (RPRX) missed or beat analyst's expectations.Jenna Brashear
What You Need to Know About Royalty Pharma plc's Q1 Earnings
Royalty Pharma plc's fiscal Q1 earnings report was released on Wednesday, February 11. Let's dive in to see if (RPRX) missed or beat analyst's expectations.Omar Beirat
Why Royalty Pharma plc’s (RPRX) Stock Is Up 5.79%
As of Wednesday, November 05, Royalty Pharma plc’s RPRX share price has surged by 5.79%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
What You Need to Know About Royalty Pharma plc's Q4 Earnings
Royalty Pharma plc's fiscal Q4 earnings report was released on Wednesday, November 05. Let's dive in to see if (RPRX) missed or beat analyst's expectations.Tudor Pop
Financial Summary
| Share Statistics | RPRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $25,904.9 | $579.1 | 88% |
|
| Shares Out (Mil) | 556.8 | 43.0 | 90% |
|
| Institutional Ownership | 93.1% | 84.3% | 63% |
|
| Float (Mil) | 413.5 | 46.8 | 84% |
|
| Beta | 0.40 | 0.62 | 22% |
|
| Avg Daily Volume (000s) | 2,611 | 285 | 86% |
|
| Price Change (52-week) |
57.4% | 63.8% | 83% |
|
| Growth | RPRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 2.3% | 6.7% | 24% |
|
| Net Income (5yr) | (4.6%) | (1.4%) | 34% |
|
| EPS (5yr) | 6.2% | 14.9% | 40 |
|
| Dividends (5yr) | 24.0% | 0.0% | 77% |
|
| Cash Flow (5yr) | (18.7%) | (14.9%) | 36% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 6 | 7 | |
| Current EPS | $1.272 | $5.228 | $5.592 | |
| Month Ago EPS | $1.275 | $5.117 | $5.614 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | $1.278 | $5.101 | $5.530 | |
| Year/Year Chg | 88.7% | 193.5% | 255.5% | |
| Financials | RPRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2,441 | $272 | 63% |
|
| Net Income (TTM) (Mil) | $826 | ($11) | 84% |
|
| EPS (TTM) | $1.921 | ($0.500) | 71% |
|
| Operating Cash Flow (TTM) (Mil) | $2,612 | ($6) | 90% |
|
| Net Cash Flow (TTM) (Mil) | ($501) | $4 | 6% |
|
| Long-Term Debt (Q1) (Mil) | $8,592 | $7 | 90% |
|
| Enterprise Value (Q1) (Mil) | $34,842 | $522 | 89% |
|
| Valuation | RPRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.76 | 2.73 | 71% |
|
| P/E | 30.7 | 20.5 | 69% |
|
| Dividend Yield | 1.6% | 0.0% | 73% |
|
| PEG (5yr hist) | 5.0 | 1.2 | 86% |
|
| Ratios | RPRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 115.0% | 65.9% | 100% |
|
| Net Margin | 33.9% | 0.7% | 92% |
|
| ROA | 4.4% | (24.6%) | 69% |
|
| ROE | 12.2% | (19.7%) | 65% |
|
| Liabilities to Assets | 49.9% | 35.5% | 42% |
|
| F-Score | 5 | 3 | 51% |
|
Royalty Pharma plc did not pass any screens on 7/31/2026.
